Next-Generation Sequencing Market and Kalorama Survey of NGS Laboratories

Next-Generation Sequencing Market and Kalorama Survey of NGS Laboratories

Next-generation sequencing (NGS) technologies encompass the modern, post-Sanger sequencing techniques that revolutionized and expanded the fields of molecular biology and genomics in recent years. NGS has been a disruptive technology that had a substantial impact on the characterization of the genome of various species and has found numerous applications in a large variety of fields, including clinical diagnostics, drug discovery and development, agriculture, and forensics. Next-Generation Sequencing Market and Kalorama Survey of NGS Laboratories provides an in-depth look at the sequencing market, including data for 2018-2023 for the following markets:

  • NGS Sequencing Market, 2018-2023
  • Estimated Sequencing System Market Revenues, 2018-2023
  • Estimated Sequencing System Consumable Market Revenues, 2018-2023
  • Estimated Sequencing System Market Revenues, 2018-2023
  • Estimated Shares by Product Type, 2018 (%)
  • Forecast Shares by Product Type, 2023 (%)
  • Regional Breakout and Market Share by Vendor
This report includes a Survey of Labs Using Next-Generation Sequencing. The survey was conducted by an experienced NGS market analyst who interviewed lab managers and directors to obtain a real-world view point on the next-generation sequencing market today.
  • Please describe the lab’s industry and function?
  • How many sequencers does the laboratory have, and which models?
  • For your most recent sequencers, please describe: the model, what applications are run typically (by percentage), how often or how many samples (runs, samples, slides, flow cells, plates, multiplexed or not).
  • Which applications are expected to increase most?
  • Does the lab outsource any sequencing? For what reason(s)?
  • How does the lab/ organization address regulated patient samples?
  • Does the lab have accreditation for regulated patient samples?
  • Which sequencers are used for regulated and non-regulated patient samples?
  • In what disease areas does the lab sequence regulated/ non-regulated patient/ human samples? What disease areas are expected to grow the most from 2017-2018?
  • What percentage of samples sequenced are patient samples subject to regulation, patient/ human samples not subject to regulation, and non-patient/ non-human samples not subject to regulation? How is this expected to change from 2017-2018
  • How much is the volume of NGS and capillary sequencing expected to change overall from 2017 to 2018?
  • What sequencer features, or steps in the sequencing process would you most like to be changed/ improved?
  • What is the main bottleneck in your sequencing process (ie at what step do things back up)?
  • How challenging are data analysis and data management?
  • Which systems would the lab most likely consider for future purchases?
  • What is the likely time-frame for future sequencer purchases?
  • Which systems are likely to be used in the future for regulated patient samples (and are not being used currently for that)?
  • What barriers or other issues would hinder the growth of sequencing, particularly NGS, in clinical areas?
Company profiles – next-generation sequencing companies:
  • 10X Genomics
  • BGI Genomics (formerly Beijing Genome Institute)
  • Illumina
  • Oxford Nanopore
  • Promega Corporation
  • Qiagen N.V.
  • Roche Diagnostics
  • Swift Biosciences
  • Thermo Fisher Scientific Inc.


  • Market Analysis and Report Summary
    • Overall Sequencing Market Revenues
      • Table NGS Sequencing Market, 2018-2023
      • Table Estimated Sequencing System Market Revenues, 2018-2023
      • Table Estimated Sequencing System Consumable Market Revenues, 2018-2023
      • Table Estimated Sequencing System Market Revenues, 2018-2023
      • Table Estimated Shares by Product Type, 2018 (%)
      • Table Forecast Shares by Product Type, 2023 (%)
      • Regional Breakout
        • Table Regional Breakout
      • Market Share
        • Table Market Share by Vendor
    • Scope
    • Methodology
    • Outline
    • Demographics
      • Regional Distribution of Respondents' Labs
        • Table Regional Distribution of Respondent Labs
        • Table Regional Distribution of Respondent Labs (%)
      • Industrial Distribution of Respondents' Labs
        • Table Primary Industry/ Segment Labs Belong To
        • Table Primary Industry/ Segment Labs Belong To (%)
        • Table Industry/ Segment(s) Labs Belong To, by Region
        • Table Industry/ Segment(s) Labs Belong To, by Region (%)
      • Laboratory Function of Respondents' Labs
        • Table Major Function(s) of Respondent Labs
        • Table Major Function(s) of Respondent Labs (%)
        • Table Major Function(s) of Labs, by Region
        • Table Major Function(s) of Labs, by Region (%)
      • Distribution by Number of Sequencers
        • Table Distribution of Total Sequencers in Labs
        • Table Number of Next-Generation Sequencers in Labs
        • Table Number of ABI Capillary Sequencers in Labs
      • Brand(s)/ Types(s) of Sequencers Owned, Overall
        • Table Brand(s)/ Type(s) of Sequencers Owned by Labs
        • Table Number of a Given Brand / Type in Labs Owning Type, 2019
        • Table Avg. Number of a Given Sequencer in Labs Owning Type, 2019
        • Table Number of a Given Brand / Type in Labs Owning Type, 2017
        • Table Avg. Number of a Given Sequencer in Labs Owning Type, 2017
      • Library Preparation and Other Automation
        • Table Library Preparation and Automation Systems
      • Position/ Role of Respondents
        • Table Position/ Role of Respondent
        • Table Position/ Role of Respondent (%)
  • System Installations
    • Overall Installed Base
      • Distribution of Sequencer Models
        • Table Sequencer Models in Respondents' Labs
        • Table Sequencer Models in Respondents' Labs (%)
        • Table Installed Base of Labs, by System(s) Owned (# of Systems)
        • Table Installed Base of Labs, by System(s) Owned (% of Systems)
      • Distribution of Number of Sequencers
        • Table Distribution of NGS vs. Capillary Systems (# of Labs)
        • Table # of NGS Systems by # of Capillary Systems (% of Labs)
        • Table # of Capillary Systems by # of NGS Systems (% of Labs)
    • Installed Base by Region
      • Overall Brand/ Type
        • Table Number of Systems Installed in Labs, by Region
        • Table Sequencer Models in Respondents' Labs, by Region (# of Systems)
        • Table Sequencer Models in Respondents' Labs, by Region (% of Systems)
      • Next-Generation Systems
        • Table NGS Models in Respondents' Labs, by Region (# of Systems)
        • Table NGS Models in Respondents' Labs, by Region (% of Systems)
      • Capillary Systems
        • Table Capillary Models in Respondents' Labs, by Region (# of Systems)
        • Table Capillary Models in Respondents' Labs, by Region (% of Systems)
    • Installed Base by Industry Segment
      • Overall Brand/ Type
        • Table Number of Systems Installed, by Industry/ Segment(s)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (# of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2017 (% of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (# of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (% of Systems)
      • Next-Generation Systems
        • Table Number of NGS Systems Installed, by Industry/ Segment
        • Table Next-Generation Models in Respondents' Labs, by Industry/ Segment (# of Systems)
        • Table Next-Generation Models in Respondents' Labs, by Industry/ Segment (% of Systems)
      • Capillary Systems
        • Table Number of Capillary Systems Installed in Labs Owning, by Industry/ Segment
    • Installed Base by Laboratory Function
      • Overall Brand/ Type
        • Table Number of Systems Installed by Laboratory Function
        • Table Brand / Type of Sequencer System Installed, by Lab Function (# of Systems)
        • Table Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
      • Next-Generation Systems
        • Table Number of NGS Installed in Labs Owning, by Lab Function
        • Table NGS Models in Respondents' Labs, by Lab Function (# of Systems)
        • Table NGS Models in Respondents' Labs, by Lab Function (% of Systems)
        • Table NGS Models in Respondents' Labs, by Lab Function (% of Systems)
      • Capillary / Gel Systems
        • Table Number of Capillary Systems Installed in Labs Owning, by Lab Function
  • Sequencer Applications, Clinical Applications, and Usage Trends
    • Sequencer Applications and Usage
      • Applications Run, Overall and by Brand/ Type
        • Table NGS Application Volume by Model (% of Sequencing)
      • Likely Increases in Applications and Volume
        • Table Applications Expected to Increase the Most, 2019
        • Table Applications Expected to Increase the Most Overall (%)
        • Table Applications Expected to Increase, by NGS Brand Owned (# of Labs)
        • Table Applications Expected to Increase, by NGS Brand Owned (% of Labs)
        • Table Expected Growth in Sequencing Volume (# of Labs)
        • Table Expected Growth in Sequencing Volume (% of Labs)
      • Capacity Usage of Systems
        • Table Avg. Percentage of Systems' Capacity Used, by Brand
        • Table Percentage of Systems' Capacity Used, by Brand
      • Outsourcing
        • Table Percentage of Sequencing Volume Outsourced
        • Table Percentage of Sequencing Volume Outsourced, by Region
        • Table Reasons for Outsourcing
        • Table Reasons for Outsourcing (%)
    • Clinical Applications
      • Sequencing of CLIA Regulated Patient Samples
        • Table How Labs Address Sequencing of Regulated Patient Samples (# of Labs)
        • Table How Labs Address Sequencing of Regulated Patient Samples (% of Labs)
      • Certification for Regulated Samples
        • Table Labs' Certification for Regulated Patient Samples
        • Table Labs' Certification for Regulated Patient Samples (%)
        • Table Distribution of Samples, Est. 2018 (# of Labs)
        • Table Distribution of Samples, Est. 2017 (% of Labs)
        • Table Distribution of Samples, Est. 2018 (% of Labs)
        • Table Distribution of Samples, Expected 2019 (# of Labs)
        • Table Distribution of Samples, Expected 2019 (% of Labs)
        • Table Proportion of Regulated vs. Non-Regulated Samples (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples, Est. 2018 (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples, Expected 2019 (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples, est. 2018 (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples, Expected 2014 (% of Sequencing)
      • Sequencers Used or Planned for Patient/ Human Samples
        • Table Sequencers Used for Regulated Patient Samples
        • Table Sequencers Used for Regulated Patient Samples (% of Systems)
      • Disease/ Therapeutic Areas Where Sequencing Applied
        • Table Disease Areas Where Sequencing Applied, NGS (Percentage and Number of Systems)
        • Table Disease Areas Where Sequencing Applied (%)
        • Table Regulated Sequencing Expected to Grow Fastest
        • Table Regulated Sequencing Expected to Grow Fastest (% of Labs)
        • Table Non-Regulated Patient/ Human Sequencing Expected to Grow Fastest
      • Challenges for Growth of Clinical Sequencing
        • Table Challenges for Growth of Clinical Sequencing
  • Preferences and Evaluations
    • Key Criteria for Choosing Sequencers
      • Overall
        • Table Most Important Criteria for Sequencer Purchase
        • Table Most Important Criteria for Sequencer Purchase (%)
      • By Next-Generation Systems vs Capillary Systems
        • Table Most Important Criteria for Purchases, by Brand Owned
    • Changes or Improvements
      • Table Feature Most Wanted to Change or Improve
      • Table Feature Most Wanted to Change or Improve (%)
    • Bottlenecks in Process
      • Table Bottlenecks in the NGS Process
      • Table Bottlenecks in the NGS Process (%)
  • Future Purchase Plans
    • Time-Frame of Purchase Plans
      • Overall
        • Table Time Frame for Future Purchase
        • Table Time Frame for Future Purchase (%)
      • By Brand/ Type Owned
        • Table Time Frame for Future Purchase, by Brand Owned (# of Labs)
        • Table Time Frame for Future Purchase, by Brand Owned (% of Labs)
      • By Laboratory Function
        • Table Time Frame for Future Purchase, by Lab Function (# of Labs)
        • Table Time Frame for Future Purchase, by Lab Function (% of Labs)
      • By Region
        • Table Time Frame for Future Purchase, by Region (# of Labs)
        • Table Time Frame for Future Purchase, by Region (% of Labs)
    • Systems Likely to Consider for Purchase
      • Overall
        • Table Sequencer Models Likely to Consider, 2019-2020
        • Table Sequencer Models Likely to Consider (% of Labs)
      • By Brand/ Type Owned
        • Table Sequencer Models Likely to Consider, by Brand/ Type Owned (# of Labs)
        • Table Sequencer Models Likely to Consider, by Brand/ Type Owned (% of Labs)
      • By Industry/ Segment
        • Table Sequencer Models Likely to Consider, by Industry/ Segment Owned (# of Labs)
        • Table Sequencer Models Likely to Consider, by Industry/ Segment Owned (% of Labs)
      • By Laboratory Function
        • Table Sequencer Models Likely to Consider, by Lab Function (# of Labs)
        • Table Sequencer Models Likely to Consider, by Lab Function (% of Labs)
      • By Region
        • Table Sequencer Models Likely to Consider, by Region (# of Labs)
        • Table Sequencer Models Likely to Consider, by Region (% of Labs)
  • Company Profiles
    • 10X Genomics
    • BGI Genomics (formerly Beijing Genome Institute)
    • Illumina
      • Key Comment
      • Recent Revenue History
      • Company Reported Highlights in 2018
    • Oxford Nanopore
    • Promega Corporation
    • QIAGEN N.V.
      • Key Comment
      • Recent Revenue History
      • Tuberculosis
      • Molecular Expansion
      • Precision Medicine / Companion Diagnostics
      • Liquid Biopsy
    • Roche Diagnostics
      • Key Comment
      • Revenues
    • Swift Biosciences
    • Thermo Fisher Scientific Inc.
      • Key Comment
      • Recent Revenue History
      • Next Generation Sequencing
  • Appendix: Library Preparation
    • Table Library Preparation Related Systems (% of Systems, Count)
    • Table Library Preparation Related Systems (% of Systems)
    • Table Library Preparation Related Systems (% of Labs Responding, Count)
    • Table Library Preparation Related Systems (% of Labs Responding)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook